

Newbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	6.3	110.6	(44.3-227.9)	Male	3	3.8	nc	(nc-nc)
Female	3	2.2	nc	(nc-nc)	Female	4	3.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.4	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	3.5	nc	(nc-nc)
Female	25	27.0	92.5	(59.8-136.5)	Female	1	3.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.3	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	12	9.9	121.3	(62.6-212.0)	Female	5	2.8	180.4	(58.1-420.9)
Female	9	9.1	99.4	(45.3-188.7)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	1	1.7	nc	(nc-nc)	Male	39	27.5	141.7	(100.8-193.7)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	0.6	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					<u>Thyroid</u>				
Male	3	2.9	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	2	2.7	nc	(nc-nc)
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.2	nc	(nc-nc)	Female	9	5.4	166.6	(76.0-316.3)
Female	0	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Leukemia</u>					<u>Liver and Intrahepatic Bile Ducts</u>				
Male	1	2.1	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Lung and Bronchus</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	13	12.5	104.4	(55.5-178.5)	Female	9	5.4	166.6	(76.0-316.3)
Female	13	11.0	117.8	(62.7-201.5)	Male	104	89.9	115.6	(94.5-140.1)
					Female	87	84.7	102.8	(82.3-126.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Newburyport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	27	18.4	146.6	(96.6-213.3)	Male	12	10.3	116.1	(59.9-202.9)
Female	7	7.4	94.8	(38.0-195.4)	Female	18	9.2	194.9	(115.4-308.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	3.6	167.3	(61.1-364.2)	Male	3	2.7	nc	(nc-nc)
Female	3	3.4	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	11	9.7	113.1	(56.4-202.4)
Female	95	80.1	118.6	(96.0-145.0)	Female	17	9.7	175.9	(102.4-281.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	3.6	nc	(nc-nc)	Male	6	7.5	80.4	(29.4-175.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	35	28.3	123.5	(86.0-171.8)	Female	9	8.4	107.3	(48.9-203.6)
Female	41	30.6	133.8	(96.0-181.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	9	5.4	167.3	(76.4-317.7)
Male	5	4.7	106.0	(34.2-247.4)	Female	5	6.4	77.9	(25.1-181.8)
Female	2	1.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	91	75.7	120.2	(96.8-147.6)
Male	2	1.5	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.3	nc	(nc-nc)	Male	1	4.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	3.3	nc	(nc-nc)
Male	10	7.9	126.0	(60.3-231.7)	<u>Testis</u>				
Female	10	5.5	183.0	(87.6-336.5)	Male	2	2.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	3.3	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	Female	5	7.5	66.9	(21.5-156.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	10	5.8	172.5	(82.6-317.2)	Female	18	16.1	111.7	(66.2-176.5)
Female	8	5.4	149.3	(64.3-294.2)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	278	250.7	110.9	(98.3-124.7)
Male	2	3.7	nc	(nc-nc)	Female	313	262.3	119.3	(106.5-133.3)
Female	0	1.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	28	35.2	79.5	(52.8-114.9)					
Female	44	34.9	126.0	(91.6-169.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Newton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	108	97.6	110.7	(90.8-133.6)	Male	56	50.8	110.2	(83.2-143.0)
Female	29	36.2	80.0	(53.6-114.9)	Female	83	43.2	192.0	(153.0-238.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	18	17.5	102.7	(60.8-162.3)	Male	20	14.1	142.3	(86.9-219.7)
Female	11	16.3	67.5	(33.6-120.7)	Female	12	11.8	101.5	(52.4-177.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	3.0	nc	(nc-nc)	Male	58	49.0	118.4	(89.9-153.0)
Female	468	372.2	125.7	(114.6-137.7)	Female	55	46.9	117.2	(88.3-152.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	16.1	55.8	(25.5-106.0)	Male	25	35.8	69.8	(45.2-103.1)
					Female	20	18.8	106.6	(65.1-164.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	142	147.2	96.5	(81.2-113.7)	Female	60	39.6	151.4	(115.5-194.9)
Female	116	150.9	76.9	(63.5-92.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	29	27.8	104.4	(69.9-149.9)
Male	14	23.8	58.8	(32.1-98.7)	Female	33	31.8	103.9	(71.5-145.9)
Female	10	7.2	138.6	(66.3-254.8)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	440	381.2	115.4	(104.9-126.7)
Male	6	7.4	81.0	(29.6-176.2)	<u>Stomach</u>				
Female	8	6.9	115.5	(49.7-227.7)	Male	22	25.0	88.0	(55.1-133.2)
<u>Kidney & Renal Pelvis</u>					Female	10	16.0	62.3	(29.8-114.7)
Male	46	39.0	118.0	(86.4-157.4)	<u>Testis</u>				
Female	26	26.2	99.1	(64.7-145.2)	Male	18	12.4	144.7	(85.7-228.6)
<u>Larynx</u>					<u>Thyroid</u>				
Male	10	16.5	60.7	(29.0-111.6)	Male	19	9.8	194.4	(117.0-303.5)
Female	4	4.6	nc	(nc-nc)	Female	41	34.1	120.2	(86.3-163.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	31	29.8	103.9	(70.6-147.5)	Female	68	75.3	90.4	(70.2-114.6)
Female	37	26.2	141.1	(99.3-194.5)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	1282	1275.0	100.5	(95.1-106.2)
Male	16	18.3	87.6	(50.0-142.2)	Female	1299	1252.5	103.7	(98.1-109.5)
Female	4	7.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	127	181.9	69.8	(58.2-83.1)					
Female	117	170.1	68.8	(56.9-82.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norfolk

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	7.6	105.3	(45.3-207.4)	Male	13	5.7	226.2	(120.3-386.8)
Female	5	1.8	270.5	(87.2-631.2)	Female	6	3.3	180.9	(66.1-393.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.2	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	5.1	nc	(nc-nc)
Female	28	27.5	102.0	(67.8-147.4)	Female	2	2.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.4	nc	(nc-nc)	Male	2	4.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	12	12.4	96.4	(49.7-168.4)	Female	1	2.7	nc	(nc-nc)
Female	3	7.4	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	2.4	253.0	(92.4-550.6)
Male	3	2.2	nc	(nc-nc)	Female	3	1.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	40	34.9	114.5	(81.8-156.0)
Male	0	1.1	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.5	nc	(nc-nc)	Male	5	2.1	241.0	(77.7-562.4)
<u>Kidney & Renal Pelvis</u>					Female	0	0.8	nc	(nc-nc)
Male	2	4.1	nc	(nc-nc)	<u>Testis</u>				
Female	4	1.7	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.6	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	3	3.2	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	3.0	nc	(nc-nc)	Female	5	5.3	93.7	(30.2-218.6)
Female	4	1.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	117	119.3	98.1	(81.1-117.6)
Male	0	2.0	nc	(nc-nc)	Female	90	80.5	111.9	(89.9-137.5)
Female	0	0.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	14	15.4	90.6	(49.5-152.1)					
Female	12	9.5	126.2	(65.1-220.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Adams

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	17.8	73.2	(38.9-125.2)	Male	4	8.9	nc	(nc-nc)
Female	6	7.6	78.8	(28.8-171.5)	Female	3	7.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.1	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	3	3.1	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	12	8.7	138.0	(71.2-241.0)
Female	53	68.7	77.1	(57.8-100.9)	Female	11	9.5	115.7	(57.7-207.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.8	nc	(nc-nc)	Male	8	6.1	130.6	(56.2-257.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	30	26.5	113.4	(76.5-161.8)	Female	9	7.5	120.1	(54.8-227.9)
Female	36	31.8	113.1	(79.2-156.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	8	5.0	160.7	(69.2-316.7)
Male	6	4.2	141.9	(51.8-308.9)	Female	6	6.8	88.8	(32.4-193.2)
Female	1	1.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	77	68.4	112.6	(88.8-140.7)
Male	0	1.3	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.3	nc	(nc-nc)	Male	1	4.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	3.4	nc	(nc-nc)
Male	9	6.9	130.8	(59.7-248.4)	<u>Testis</u>				
Female	6	5.2	114.7	(41.9-249.8)	Male	3	2.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	2.9	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
Female	3	0.9	nc	(nc-nc)	Female	3	5.6	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	10	5.4	186.8	(89.4-343.6)	Female	15	13.9	107.6	(60.2-177.5)
Female	4	5.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	251	228.5	109.9	(96.7-124.3)
Male	1	3.2	nc	(nc-nc)	Female	239	244.9	97.6	(85.6-110.8)
Female	2	1.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	43	33.1	129.8	(93.9-174.8)					
Female	42	35.1	119.6	(86.2-161.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Andover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	32	26.6	120.4	(82.3-169.9)	Male	20	14.7	136.2	(83.2-210.4)
Female	8	10.8	74.4	(32.0-146.6)	Female	18	12.8	140.6	(83.3-222.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	5.3	93.9	(30.3-219.1)	Male	5	3.9	128.3	(41.3-299.3)
Female	7	4.9	142.1	(56.9-292.8)	Female	6	3.5	171.0	(62.5-372.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	0.8	nc	(nc-nc)	Male	19	14.0	135.5	(81.6-211.7)
Female	115	109.2	105.3	(87.0-126.4)	Female	10	14.0	71.6	(34.3-131.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	4.9	nc	(nc-nc)	Male	8	10.4	77.2	(33.2-152.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	34	40.6	83.8	(58.0-117.1)	Female	17	11.7	145.6	(84.8-233.2)
Female	54	45.6	118.3	(88.9-154.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	12	7.7	156.4	(80.7-273.2)
Male	8	6.6	120.8	(52.0-238.1)	Female	6	9.5	63.0	(23.0-137.0)
Female	4	2.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	116	104.5	111.0	(91.7-133.1)
Male	2	2.3	nc	(nc-nc)	<u>Stomach</u>				
Female	1	2.0	nc	(nc-nc)	Male	9	6.9	130.2	(59.4-247.1)
<u>Kidney & Renal Pelvis</u>					Female	5	4.9	101.0	(32.6-235.8)
Male	12	11.1	108.0	(55.7-188.7)	<u>Testis</u>				
Female	8	7.7	103.8	(44.7-204.5)	Male	2	4.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	4.6	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	7	10.3	68.2	(27.3-140.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	8.6	92.9	(40.0-183.0)	Female	22	21.6	101.9	(63.8-154.3)
Female	7	8.1	86.8	(34.8-178.9)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	374	355.1	105.3	(94.9-116.6)
Male	1	5.2	nc	(nc-nc)	Female	371	370.6	100.1	(90.2-110.8)
Female	2	2.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	43	49.6	86.6	(62.7-116.7)					
Female	43	49.3	87.3	(63.2-117.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Attleborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	22.3	94.0	(58.2-143.7)	Male	19	13.5	141.1	(84.9-220.4)
Female	4	8.0	nc	(nc-nc)	Female	10	11.6	86.0	(41.2-158.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	5.0	178.6	(81.5-339.0)	Male	2	3.4	nc	(nc-nc)
Female	5	4.3	115.0	(37.1-268.4)	Female	5	2.6	190.6	(61.4-444.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.7	nc	(nc-nc)	Male	14	12.6	111.1	(60.7-186.5)
Female	108	94.7	114.0	(93.5-137.6)	Female	10	11.1	90.3	(43.2-166.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	4.7	nc	(nc-nc)	Male	7	9.5	73.5	(29.4-151.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	41	34.6	118.4	(84.9-160.6)	Female	12	9.9	121.8	(62.9-212.8)
Female	23	32.9	70.0	(44.3-105.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	10	6.6	152.6	(73.0-280.6)
Male	8	5.8	137.3	(59.1-270.6)	Female	6	6.9	87.4	(31.9-190.1)
Female	0	1.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	88	93.3	94.3	(75.7-116.2)
Male	3	2.3	nc	(nc-nc)	<u>Stomach</u>				
Female	4	2.0	nc	(nc-nc)	Male	5	5.8	85.8	(27.6-200.1)
<u>Kidney & Renal Pelvis</u>					Female	2	3.4	nc	(nc-nc)
Male	12	10.1	119.1	(61.4-208.0)	<u>Testis</u>				
Female	3	6.3	nc	(nc-nc)	Male	6	4.5	134.2	(49.0-292.1)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	4.1	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	12	10.4	115.6	(59.7-202.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	7.7	nc	(nc-nc)	Female	21	18.8	111.8	(69.2-170.9)
Female	9	6.3	141.8	(64.7-269.2)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	337	313.8	107.4	(96.2-119.5)
Male	3	4.7	nc	(nc-nc)	Female	311	303.4	102.5	(91.4-114.5)
Female	0	1.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	59	43.2	136.6	(104.0-176.2)					
Female	38	39.0	97.4	(68.9-133.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	5.0	160.5	(69.1-316.3)	Male	3	2.7	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.0	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	2.6	nc	(nc-nc)
Female	19	18.6	102.4	(61.6-159.9)	Female	0	2.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.8	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	7.6	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
Female	6	7.2	83.9	(30.6-182.6)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	1.2	nc	(nc-nc)	Male	17	19.3	87.9	(51.2-140.7)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	2.0	nc	(nc-nc)	Female	4	3.7	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Liver and Intrahepatic Bile Ducts</u>				
Male	0	0.9	nc	(nc-nc)	Male	3	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					<u>Lung and Bronchus</u>				
Male	2	1.6	nc	(nc-nc)	Male	6	9.4	64.1	(23.4-139.5)
Female	0	1.3	nc	(nc-nc)	Female	7	8.5	82.3	(33.0-169.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Reading

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	12.7	71.0	(32.4-134.8)	Male	11	7.5	146.1	(72.9-261.5)
Female	1	4.3	nc	(nc-nc)	Female	7	6.1	115.2	(46.2-237.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.8	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	3	7.0	nc	(nc-nc)
Female	62	51.7	120.0	(92.0-153.8)	Female	6	5.9	102.0	(37.3-222.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.5	nc	(nc-nc)	Male	5	5.5	90.5	(29.2-211.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	13	19.7	66.1	(35.2-113.0)	Female	6	5.3	112.9	(41.2-245.8)
Female	18	17.3	104.3	(61.8-164.8)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	4	3.4	nc	(nc-nc)	Male	51	55.9	91.2	(67.9-119.9)
Female	0	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	1.2	nc	(nc-nc)	Male	5	2.1	236.0	(76.1-550.9)
Female	0	0.9	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	5.8	136.8	(58.9-269.6)	Female	5	10.4	47.9	(15.4-111.8)
Female	3	3.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Liver and Intrahepatic Bile Ducts</u>				
Male	1	2.4	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Leukemia</u>					<u>Lung and Bronchus</u>				
Male	2	4.2	nc	(nc-nc)	Male	19	25.2	75.5	(45.4-117.9)
Female	3	3.3	nc	(nc-nc)	Female	24	21.4	112.2	(71.8-166.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	26	29.7	87.4	(57.1-128.1)	Male	15	16.2	92.8	(51.9-153.1)
Female	13	11.8	110.3	(58.7-188.7)	Female	13	14.6	89.3	(47.5-152.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	5.5	nc	(nc-nc)	Male	4	4.3	nc	(nc-nc)
Female	1	5.4	nc	(nc-nc)	Female	2	3.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.9	nc	(nc-nc)	Male	12	15.4	78.0	(40.3-136.2)
Female	133	119.7	111.2	(93.1-131.7)	Female	11	15.5	70.8	(35.3-126.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	5.4	165.5	(75.5-314.2)	Male	15	11.3	132.8	(74.3-219.1)
<u>Colon / Rectum</u>					Female	12	6.1	196.5	(101.4-343.3)
Male	50	45.3	110.5	(82.0-145.7)	<u>Ovary</u>				
Female	42	50.3	83.5	(60.2-112.8)	Female	17	12.9	131.3	(76.5-210.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	7.3	109.2	(47.0-215.1)	Male	6	8.5	70.4	(25.7-153.3)
Female	3	2.4	nc	(nc-nc)	Female	3	10.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.4	nc	(nc-nc)	Male	86	115.6	74.4	(59.5-91.9)
Female	2	2.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	7.7	78.1	(28.5-169.9)
Male	11	12.2	90.3	(45.0-161.5)	Female	4	5.5	nc	(nc-nc)
Female	17	8.5	201.1	(117.1-321.9)	<u>Testis</u>				
<u>Larynx</u>					Male	6	4.4	137.9	(50.4-300.2)
Male	7	5.1	137.9	(55.2-284.1)	<u>Thyroid</u>				
Female	0	1.4	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
<u>Leukemia</u>					Female	11	12.1	91.1	(45.4-163.0)
Male	7	9.2	76.0	(30.4-156.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	8.8	56.9	(18.3-132.7)	Female	18	23.5	76.5	(45.3-120.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	5.8	nc	(nc-nc)	Male	355	392.7	90.4	(81.2-100.3)
Female	2	2.4	nc	(nc-nc)	Female	404	409.1	98.7	(89.3-108.9)
<u>Lung and Bronchus</u>									
Male	58	55.8	104.0	(79.0-134.5)					
Female	65	54.0	120.3	(92.8-153.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	12.0	nc	(nc-nc)	Male	3	7.3	nc	(nc-nc)
Female	1	4.1	nc	(nc-nc)	Female	5	6.0	82.7	(26.6-193.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.7	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
Female	1	2.3	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	6	6.8	88.4	(32.3-192.5)
Female	45	51.0	88.3	(64.4-118.1)	Female	3	5.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.5	nc	(nc-nc)	Male	8	5.3	149.6	(64.4-294.8)
<u>Colon / Rectum</u>					Female	7	2.4	292.3	(117.1-602.4)
Male	12	18.7	64.1	(33.1-111.9)	<u>Ovary</u>				
Female	19	16.5	115.2	(69.3-179.8)	Female	5	5.2	95.9	(30.9-223.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	3.2	nc	(nc-nc)	Male	2	3.6	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	Female	2	3.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.2	nc	(nc-nc)	Male	56	52.7	106.2	(80.2-137.9)
Female	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.1	nc	(nc-nc)
Male	6	5.6	106.9	(39.0-232.6)	Female	1	1.7	nc	(nc-nc)
Female	4	3.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.1	nc	(nc-nc)
Male	1	2.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
<u>Leukemia</u>					Female	7	5.3	130.9	(52.5-269.8)
Male	1	4.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	3.2	nc	(nc-nc)	Female	9	10.2	88.4	(40.3-167.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.7	nc	(nc-nc)	Male	142	172.4	82.4	(69.4-97.1)
Female	1	0.8	nc	(nc-nc)	Female	148	158.8	93.2	(78.8-109.5)
<u>Lung and Bronchus</u>									
Male	17	23.8	71.3	(41.5-114.1)					
Female	21	20.5	102.5	(63.4-156.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	13.3	82.5	(41.1-147.6)	Male	9	7.2	125.4	(57.2-238.0)
Female	2	5.4	nc	(nc-nc)	Female	4	6.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.6	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	1	2.4	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	5	6.9	72.4	(23.3-168.9)
Female	50	52.9	94.6	(70.2-124.7)	Female	10	7.0	143.8	(68.8-264.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	2.4	254.8	(93.1-554.7)	Male	6	5.0	120.9	(44.1-263.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	17	20.2	84.2	(49.0-134.9)	Female	4	5.7	nc	(nc-nc)
Female	26	23.0	113.0	(73.8-165.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	3.8	nc	(nc-nc)
Male	1	3.2	nc	(nc-nc)	Female	5	4.8	104.0	(33.5-242.6)
Female	1	1.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	51	50.9	100.2	(74.6-131.8)
Male	0	1.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.0	nc	(nc-nc)	Male	6	3.4	174.0	(63.5-378.8)
<u>Kidney & Renal Pelvis</u>					Female	0	2.5	nc	(nc-nc)
Male	8	5.4	148.0	(63.7-291.6)	<u>Testis</u>				
Female	5	3.8	131.4	(42.4-306.7)	Male	1	2.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	2.2	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	4	5.0	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	4.3	nc	(nc-nc)	Female	16	10.4	153.2	(87.5-248.8)
Female	1	4.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	159	174.8	91.0	(77.4-106.3)
Male	3	2.5	nc	(nc-nc)	Female	169	182.8	92.5	(79.0-107.5)
Female	0	1.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	22	24.7	89.2	(55.9-135.1)					
Female	19	24.5	77.6	(46.7-121.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	3.2	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.6	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	17	12.6	135.1	(78.7-216.3)	Female	3	1.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.6	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	4.9	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
Female	6	4.8	125.9	(46.0-274.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	1	0.8	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.3	nc	(nc-nc)	Male	7	13.2	52.9	(21.2-108.9)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	0	1.4	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	3	0.9	nc	(nc-nc)	Female	2	0.5	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	1	1.0	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.7	nc	(nc-nc)	Female	5	2.5	200.6	(64.6-468.0)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	3	6.2	nc	(nc-nc)	Male	28	43.6	64.3	(42.7-92.9)
Female	4	5.6	nc	(nc-nc)	Female	51	41.2	123.9	(92.2-162.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	12.2	90.0	(44.9-161.0)	Male	7	7.8	89.7	(35.9-184.8)
Female	4	4.5	nc	(nc-nc)	Female	16	7.0	227.7	(130.1-369.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	3.0	197.2	(72.0-429.2)	Male	1	1.9	nc	(nc-nc)
Female	2	2.7	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	3	7.2	nc	(nc-nc)
Female	38	55.5	68.5	(48.5-94.0)	Female	9	6.4	139.7	(63.8-265.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	2.9	nc	(nc-nc)	Male	3	5.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	23	19.2	119.7	(75.8-179.5)	Female	5	5.8	86.1	(27.7-200.8)
Female	13	18.8	69.3	(36.8-118.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	3.7	nc	(nc-nc)
Male	4	3.3	nc	(nc-nc)	Female	6	3.9	154.8	(56.5-336.8)
Female	1	0.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	49	52.8	92.9	(68.7-122.8)
Male	0	1.5	nc	(nc-nc)	<u>Stomach</u>				
Female	2	1.4	nc	(nc-nc)	Male	4	3.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	4	2.0	nc	(nc-nc)
Male	8	5.8	137.5	(59.2-270.9)	<u>Testis</u>				
Female	4	3.6	nc	(nc-nc)	Male	5	2.8	177.4	(57.2-414.1)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	2.4	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	3	0.6	nc	(nc-nc)	Female	8	6.5	122.4	(52.7-241.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	4.4	nc	(nc-nc)	Female	10	11.0	91.2	(43.6-167.7)
Female	2	3.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	180	177.6	101.4	(87.1-117.3)
Male	4	2.7	nc	(nc-nc)	Female	171	177.0	96.6	(82.7-112.2)
Female	1	0.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	30	23.9	125.5	(84.6-179.1)					
Female	22	22.0	100.2	(62.7-151.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norwell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	10.6	113.2	(58.4-197.8)	Male	9	5.9	151.5	(69.1-287.6)
Female	2	3.7	nc	(nc-nc)	Female	10	4.7	213.1	(102.0-391.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.1	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	3	1.8	nc	(nc-nc)	Female	3	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	9	5.6	160.5	(73.3-304.8)
Female	50	41.7	119.9	(89.0-158.1)	Female	5	4.9	102.8	(33.1-239.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.8	nc	(nc-nc)	Male	2	4.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	15	16.4	91.6	(51.2-151.1)	Female	3	4.3	nc	(nc-nc)
Female	15	15.3	98.0	(54.8-161.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	3.1	nc	(nc-nc)
Male	4	2.8	nc	(nc-nc)	Female	2	3.2	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	41	45.5	90.0	(64.6-122.1)
Male	2	0.8	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.7	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.6	nc	(nc-nc)
Male	3	4.7	nc	(nc-nc)	<u>Testis</u>				
Female	5	2.8	179.0	(57.7-417.6)	Male	0	1.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	2.0	nc	(nc-nc)	Male	4	1.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	7	3.8	185.5	(74.3-382.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	3.4	nc	(nc-nc)	Female	13	8.5	152.5	(81.1-260.8)
Female	2	2.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	133	147.0	90.5	(75.8-107.2)
Male	2	2.2	nc	(nc-nc)	Female	143	134.1	106.6	(89.8-125.6)
Female	1	0.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	13	20.5	63.3	(33.7-108.3)					
Female	11	17.6	62.5	(31.2-111.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norwood

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	32	35.1	91.3	(62.4-128.9)	Male	26	17.9	145.6	(95.1-213.3)
Female	11	13.9	79.0	(39.4-141.3)	Female	19	15.3	124.3	(74.8-194.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	12	6.1	196.7	(101.5-343.6)	Male	9	5.0	180.0	(82.1-341.7)
Female	10	5.8	171.5	(82.1-315.5)	Female	6	4.5	132.3	(48.3-288.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.1	nc	(nc-nc)	Male	13	17.3	75.1	(40.0-128.5)
Female	111	131.5	84.4	(69.4-101.7)	Female	16	17.6	91.0	(52.0-147.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	5.6	nc	(nc-nc)	Male	5	12.2	41.0	(13.2-95.7)
<u>Colon / Rectum</u>					Female	6	6.8	87.7	(32.0-190.9)
Male	66	52.4	125.9	(97.4-160.2)	<u>Ovary</u>				
Female	59	57.8	102.0	(77.7-131.6)	Female	15	14.2	105.8	(59.2-174.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	8.4	95.5	(41.1-188.1)	Male	9	9.9	91.3	(41.7-173.3)
Female	3	2.8	nc	(nc-nc)	Female	13	12.3	106.0	(56.4-181.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.6	nc	(nc-nc)	Male	166	135.0	123.0	(105.0-143.2)
Female	1	2.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	12	8.9	134.9	(69.6-235.7)
Male	8	13.7	58.5	(25.2-115.2)	Female	5	6.2	80.6	(26.0-188.1)
Female	16	9.7	164.7	(94.1-267.5)	<u>Testis</u>				
<u>Larynx</u>					Male	4	4.7	nc	(nc-nc)
Male	9	5.8	155.8	(71.1-295.8)	<u>Thyroid</u>				
Female	0	1.7	nc	(nc-nc)	Male	5	3.4	145.7	(47.0-340.0)
<u>Leukemia</u>					Female	10	11.6	86.6	(41.4-159.2)
Male	14	10.6	132.0	(72.1-221.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	10	9.8	101.9	(48.8-187.4)	Female	26	26.6	97.6	(63.7-143.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	6.3	94.7	(34.6-206.1)	Male	501	452.6	110.7	(101.2-120.8)
Female	3	2.8	nc	(nc-nc)	Female	472	459.1	102.8	(93.7-112.5)
<u>Lung and Bronchus</u>									
Male	67	65.5	102.3	(79.3-130.0)					
Female	74	64.6	114.6	(90.0-143.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Oak Bluffs

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	3.9	155.4	(56.7-338.1)	Male	3	2.2	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	0.8	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
Female	21	16.3	128.7	(79.7-196.8)	Female	4	2.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.7	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	6	5.9	101.5	(37.0-220.8)	Female	1	1.7	nc	(nc-nc)
Female	3	6.4	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	1.1	nc	(nc-nc)
Male	2	1.0	nc	(nc-nc)	Female	4	1.4	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	20	15.8	126.3	(77.1-195.1)
Male	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.3	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.7	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	<u>Testis</u>				
Female	1	1.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	0.7	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	1.2	405.0	(130.5-945.2)	Female	3	3.3	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	69	52.7	131.0	(101.9-165.8)
Male	0	0.8	nc	(nc-nc)	Female	63	54.5	115.6	(88.8-147.9)
Female	0	0.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	12	7.4	161.2	(83.2-281.5)					
Female	8	7.6	105.3	(45.3-207.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Oakham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.4	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	5.6	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	2.2	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	3	1.6	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	6	5.9	102.2	(37.3-222.4)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	0.7	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Liver and Intrahepatic Bile Ducts</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					<u>Lung and Bronchus</u>				
Male	2	0.5	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.3	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					<u>Male</u>				
Male	1	2.7	nc	(nc-nc)	Male	20	19.9	100.6	(61.4-155.4)
Female	1	2.0	nc	(nc-nc)	Female	13	16.7	78.1	(41.5-133.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Orange

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	8.1	86.1	(34.5-177.4)	Male	2	4.4	nc	(nc-nc)
Female	3	3.0	nc	(nc-nc)	Female	4	3.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.6	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	6	4.2	143.0	(52.2-311.3)
Female	22	31.3	70.2	(44.0-106.3)	Female	4	4.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	1.4	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	12.4	nc	(nc-nc)	Female	4	3.3	nc	(nc-nc)
Female	12	12.5	96.1	(49.6-167.9)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	2	2.0	nc	(nc-nc)	Male	27	33.1	81.6	(53.7-118.7)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.6	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	3.4	nc	(nc-nc)	Female	8	6.3	126.4	(54.4-249.1)
Female	2	2.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	1	1.4	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	2	1.6	nc	(nc-nc)	Male	12	15.7	76.4	(39.4-133.5)
Female	0	0.6	nc	(nc-nc)	Female	14	14.5	96.6	(52.8-162.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Orleans

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	27	16.1	167.7	(110.5-244.1)	Male	13	6.9	189.1	(100.6-323.4)
Female	8	5.5	145.6	(62.7-286.8)	Female	9	4.7	189.5	(86.5-359.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	2.1	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	5	6.9	72.2	(23.3-168.5)
Female	72	46.2	156.0	(122.1-196.5)	Female	13	6.5	199.0	(105.9-340.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.5	nc	(nc-nc)	Male	2	4.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	23	23.4	98.3	(62.3-147.5)	Female	3	5.0	nc	(nc-nc)
Female	25	22.7	110.2	(71.3-162.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	4.4	nc	(nc-nc)
Male	1	3.7	nc	(nc-nc)	Female	4	4.9	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	92	60.7	151.5	(122.1-185.8)
Male	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.5	nc	(nc-nc)	Male	2	3.9	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	2.4	nc	(nc-nc)
Male	2	5.6	nc	(nc-nc)	<u>Testis</u>				
Female	4	3.6	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	5	2.5	201.1	(64.8-469.3)	Male	0	1.0	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	5	2.7	181.9	(58.6-424.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	11	4.3	258.2	(128.7-462.0)	Female	14	9.8	143.5	(78.4-240.8)
Female	5	3.5	144.0	(46.4-336.1)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	226	195.7	115.5	(100.9-131.5)
Male	2	2.6	nc	(nc-nc)	Female	219	167.5	130.8	(114.0-149.3)
Female	2	1.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	21	29.7	70.8	(43.8-108.2)					
Female	30	25.5	117.6	(79.3-167.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Otis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.8	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.3	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	5	5.7	88.4	(28.5-206.3)	Female	1	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	2.8	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	1	0.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.1	nc	(nc-nc)	Female	4	7.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	2	0.8	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	2	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	1	0.6	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	0	0.4	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	5	3.6	140.3	(45.2-327.4)	Female	28	25.0	112.1	(74.5-162.0)
Female	4	2.5	nc	(nc-nc)	Female	15	17.9	83.9	(46.9-138.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Oxford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	12.3	146.6	(86.9-231.7)	Male	7	7.1	99.1	(39.7-204.2)
Female	10	4.4	228.0	(109.1-419.3)	Female	5	6.0	83.3	(26.9-194.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.6	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	5	2.3	221.8	(71.5-517.7)	Female	1	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	6	6.7	90.1	(32.9-196.0)
Female	57	50.1	113.9	(86.2-147.5)	Female	6	6.0	100.6	(36.7-218.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.4	nc	(nc-nc)	Male	5	5.0	100.5	(32.4-234.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	16	18.8	85.0	(48.6-138.1)	Female	6	5.2	115.0	(42.0-250.4)
Female	12	17.8	67.4	(34.8-117.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	3.6	nc	(nc-nc)
Male	1	3.1	nc	(nc-nc)	Female	7	3.8	186.3	(74.6-383.9)
Female	0	0.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	42	50.2	83.6	(60.2-113.0)
Male	3	1.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.0	nc	(nc-nc)	Male	3	3.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.8	nc	(nc-nc)
Male	6	5.3	112.3	(41.0-244.5)	<u>Testis</u>				
Female	1	3.4	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	2.2	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	5	5.2	96.4	(31.1-224.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	4.1	123.1	(39.7-287.3)	Female	8	10.0	80.1	(34.5-157.9)
Female	2	3.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	171	168.4	101.5	(86.9-117.9)
Male	4	2.5	nc	(nc-nc)	Female	160	161.9	98.8	(84.1-115.4)
Female	0	0.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	26	23.5	110.4	(72.1-161.8)					
Female	16	21.6	74.1	(42.3-120.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Palmer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	13.8	130.9	(77.5-206.8)	Male	6	7.3	81.9	(29.9-178.3)
Female	7	5.5	127.9	(51.3-263.6)	Female	2	6.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.6	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	3	2.4	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	3	7.0	nc	(nc-nc)
Female	54	53.6	100.7	(75.7-131.4)	Female	2	7.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.3	nc	(nc-nc)	Male	9	5.1	177.8	(81.1-337.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	22	20.8	105.9	(66.3-160.3)	Female	7	5.7	122.1	(48.9-251.6)
Female	29	22.8	127.3	(85.2-182.9)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	3	3.4	nc	(nc-nc)	Male	49	53.8	91.1	(67.4-120.5)
Female	0	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	1.1	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	5.6	89.3	(28.8-208.4)	Female	17	10.7	159.0	(92.6-254.6)
Female	6	3.9	153.8	(56.2-334.9)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Liver and Intrahepatic Bile Ducts</u>				
Male	3	2.3	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Leukemia</u>					<u>Lung and Bronchus</u>				
Male	2	4.3	nc	(nc-nc)	Male	32	26.0	123.1	(84.2-173.8)
Female	1	3.9	nc	(nc-nc)	Female	20	25.6	78.1	(47.7-120.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Paxton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	5.6	nc	(nc-nc)	Male	1	2.8	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.0	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	10	17.8	56.0	(26.8-103.1)	Female	2	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.8	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	8.4	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
Female	5	6.6	75.5	(24.3-176.1)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	2	1.4	nc	(nc-nc)	Male	15	22.1	67.8	(37.9-111.8)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.4	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	2.2	nc	(nc-nc)	Female	2	3.6	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	1	1.0	nc	(nc-nc)	Male	4	1.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	0	1.0	nc	(nc-nc)	Male	9	10.6	84.9	(38.7-161.2)
Female	0	0.3	nc	(nc-nc)	Female	3	8.1	nc	(nc-nc)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	9	10.6	84.9	(38.7-161.2)	Male	56	72.9	76.8	(58.0-99.8)
Female	3	8.1	nc	(nc-nc)	Female	40	58.6	68.3	(48.8-93.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Peabody

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	79	61.1	129.2	(102.3-161.0)	Male	27	31.6	85.5	(56.3-124.3)
Female	34	23.2	146.8	(101.7-205.2)	Female	30	25.8	116.3	(78.4-166.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	11	10.8	101.6	(50.6-181.7)	Male	8	8.8	90.8	(39.1-178.9)
Female	11	9.9	111.3	(55.5-199.1)	Female	12	7.6	158.6	(81.8-277.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.9	nc	(nc-nc)	Male	35	30.4	115.1	(80.1-160.0)
Female	256	228.4	112.1	(98.8-126.7)	Female	36	29.4	122.3	(85.6-169.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	9.5	94.6	(43.2-179.5)	Male	23	22.4	102.6	(65.0-153.9)
					Female	7	11.6	60.2	(24.1-124.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	112	92.1	121.6	(100.1-146.3)	Female	24	24.3	98.8	(63.3-146.9)
Female	111	94.7	117.2	(96.4-141.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	19	17.4	109.1	(65.6-170.4)
Male	16	15.1	106.0	(60.5-172.1)	Female	24	20.2	119.0	(76.2-177.1)
Female	4	4.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	233	248.4	93.8	(82.2-106.7)
Male	6	4.3	138.3	(50.5-301.1)	<u>Stomach</u>				
Female	3	3.7	nc	(nc-nc)	Male	19	15.4	123.2	(74.1-192.3)
<u>Kidney & Renal Pelvis</u>					Female	14	9.9	140.8	(76.9-236.3)
Male	22	24.8	88.7	(55.5-134.2)	<u>Testis</u>				
Female	11	16.6	66.2	(33.0-118.4)	Male	9	7.3	122.7	(56.0-232.9)
<u>Larynx</u>					<u>Thyroid</u>				
Male	12	10.6	113.7	(58.7-198.6)	Male	7	6.1	115.0	(46.1-236.9)
Female	2	3.0	nc	(nc-nc)	Female	24	19.4	123.7	(79.2-184.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	27	18.5	145.9	(96.1-212.3)	Female	54	46.8	115.3	(86.6-150.5)
Female	23	16.2	142.2	(90.1-213.4)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	869	809.1	107.4	(100.4-114.8)
Male	11	11.5	95.8	(47.7-171.4)	Female	904	778.4	116.1	(108.7-124.0)
Female	7	4.6	152.2	(61.0-313.5)					
<u>Lung and Bronchus</u>									
Male	135	116.9	115.4	(96.8-136.6)					
Female	130	110.4	117.7	(98.4-139.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pelham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.8	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	6	6.1	98.7	(36.0-214.8)	Female	2	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	2.7	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	0	1.9	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.5	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	10	7.4	134.3	(64.3-247.0)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	0	0.7	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.3	nc	(nc-nc)	Male	2	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.5	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.4	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	3	3.4	nc	(nc-nc)	Male	22	24.0	91.8	(57.5-139.0)
Female	0	2.5	nc	(nc-nc)	Female	13	18.5	70.1	(37.3-120.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pembroke

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	13.4	156.9	(97.1-239.8)	Male	12	8.4	143.2	(73.9-250.1)
Female	1	4.6	nc	(nc-nc)	Female	11	7.0	156.5	(78.0-280.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.2	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
Female	5	2.6	190.5	(61.4-444.5)	Female	2	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	8	7.7	103.3	(44.5-203.6)
Female	62	58.2	106.6	(81.7-136.6)	Female	7	6.4	108.8	(43.6-224.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.9	nc	(nc-nc)	Male	6	6.2	96.9	(35.4-210.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	10	21.0	47.6	(22.8-87.5)	Female	5	5.9	84.0	(27.1-196.1)
Female	14	18.2	77.0	(42.0-129.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	8	4.0	199.3	(85.8-392.8)
Male	6	3.7	163.2	(59.6-355.2)	Female	6	3.8	158.0	(57.7-343.9)
Female	0	0.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	52	60.5	86.0	(64.2-112.8)
Male	3	1.4	nc	(nc-nc)	<u>Stomach</u>				
Female	2	1.2	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	1.9	nc	(nc-nc)
Male	6	6.4	93.3	(34.1-203.2)	<u>Testis</u>				
Female	2	3.8	nc	(nc-nc)	Male	4	2.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	2.6	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	6	6.4	94.4	(34.5-205.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	4.7	nc	(nc-nc)	Female	12	11.8	102.0	(52.6-178.1)
Female	3	3.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	193	196.2	98.4	(85.0-113.3)
Male	1	3.0	nc	(nc-nc)	Female	199	180.1	110.5	(95.7-127.0)
Female	0	0.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	31	26.6	116.4	(79.1-165.2)					
Female	34	23.0	147.8	(102.3-206.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pepperell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	7.4	94.4	(37.8-194.6)	Male	4	5.0	nc	(nc-nc)
Female	3	2.7	nc	(nc-nc)	Female	4	4.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	2.0	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	2	4.6	nc	(nc-nc)
Female	31	35.8	86.6	(58.8-122.9)	Female	6	3.9	152.0	(55.5-330.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	1.9	323.1	(118.0-703.3)	Male	1	3.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	12	11.8	101.5	(52.4-177.3)	Female	3	3.7	nc	(nc-nc)
Female	12	11.2	107.0	(55.2-186.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	2.2	nc	(nc-nc)
Male	3	2.1	nc	(nc-nc)	Female	1	2.3	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	34	32.6	104.3	(72.2-145.8)
Male	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.8	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.2	nc	(nc-nc)
Male	2	3.7	nc	(nc-nc)	<u>Testis</u>				
Female	3	2.3	nc	(nc-nc)	Male	4	1.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.5	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	4	4.1	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	2.8	nc	(nc-nc)	Female	9	7.0	128.5	(58.6-243.9)
Female	3	2.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	96	110.4	87.0	(70.4-106.2)
Male	2	1.8	nc	(nc-nc)	Female	112	110.6	101.2	(83.4-121.8)
Female	2	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	11	14.8	74.5	(37.1-133.3)					
Female	14	13.6	102.7	(56.1-172.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Peru

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	0.8	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	2.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	1.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	3.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Male</u>				
Male	0	0.2	nc	(nc-nc)	9	11.2	80.0	(36.5-151.9)	
Female	0	0.0	nc	(nc-nc)	<u>Female</u>				
<u>Leukemia</u>					1				
Male	1	0.3	nc	(nc-nc)	7.5	nc	(nc-nc)		
Female	0	0.2	nc	(nc-nc)	<u>Liver and Intrahepatic Bile Ducts</u>				
<u>Lung and Bronchus</u>					<u>Male</u>				
Male	0	1.5	nc	(nc-nc)	0	0.2	nc	(nc-nc)	
Female	0	0.9	nc	(nc-nc)	<u>Female</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					0				
<u>Lung and Bronchus</u>					0.0				
<u>Liver and Intrahepatic Bile Ducts</u>					nc				
<u>Liver and Intrahepatic Bile Ducts</u>					(nc-nc)				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Petersham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.6	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	4	0.8	nc	(nc-nc)
Female	8	5.7	140.8	(60.6-277.4)	Female	0	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	2.4	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
Female	1	2.4	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	6	6.5	92.0	(33.6-200.2)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	0.3	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.5	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	20	21.0	95.2	(58.2-147.1)
Male	0	0.3	nc	(nc-nc)	Female	16	19.3	82.7	(47.2-134.3)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	3	3.0	nc	(nc-nc)					
Female	0	2.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Phillipston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.4	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	4	5.0	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	2.2	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	2	5.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.6	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Male</u>				
Male	0	0.3	nc	(nc-nc)	13	19.7	65.9	(35.1-112.8)	
Female	0	0.1	nc	(nc-nc)	<u>Female</u>				
<u>Leukemia</u>					10				
Male	0	0.5	nc	(nc-nc)	15.2	65.9	(31.5-121.2)		
Female	1	0.3	nc	(nc-nc)	<u>Liver and Intrahepatic Bile Ducts</u>				
Male	0	0.3	nc	(nc-nc)	<u>Male</u>				
Female	0	0.1	nc	(nc-nc)	<u>Female</u>				
<u>Lung and Bronchus</u>					<u>Male</u>				
Male	1	2.6	nc	(nc-nc)	<u>Female</u>				
Female	2	1.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pittsfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	67	59.8	112.1	(86.9-142.4)	Male	40	29.7	134.6	(96.2-183.4)
Female	25	23.5	106.5	(68.9-157.2)	Female	35	24.7	141.5	(98.6-196.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	10.1	79.0	(34.0-155.6)	Male	6	8.5	70.8	(25.8-154.1)
Female	9	9.6	93.4	(42.6-177.3)	Female	5	7.6	65.5	(21.1-152.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.8	nc	(nc-nc)	Male	36	29.0	124.2	(87.0-172.0)
Female	210	219.2	95.8	(83.3-109.7)	Female	29	29.4	98.7	(66.1-141.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	13	8.9	146.4	(77.9-250.3)	Male	22	20.6	107.0	(67.0-162.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	117	89.1	131.3	(108.6-157.4)	Female	21	23.6	88.9	(55.0-135.9)
Female	79	97.5	81.0	(64.2-101.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	31	16.8	184.9	(125.6-262.5)
Male	19	14.2	133.5	(80.3-208.4)	Female	18	20.7	86.8	(51.4-137.3)
Female	5	4.7	107.5	(34.6-250.8)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	222	230.2	96.4	(84.2-110.0)
Male	4	4.1	nc	(nc-nc)	<u>Stomach</u>				
Female	3	3.6	nc	(nc-nc)	Male	10	15.1	66.3	(31.7-121.9)
<u>Kidney & Renal Pelvis</u>					Female	7	10.4	67.5	(27.0-139.1)
Male	19	23.1	82.4	(49.6-128.7)	<u>Testis</u>				
Female	14	16.3	85.8	(46.9-144.0)	Male	7	6.8	103.2	(41.4-212.7)
<u>Larynx</u>					<u>Thyroid</u>				
Male	8	9.8	81.6	(35.1-160.8)	Male	8	5.5	145.2	(62.5-286.1)
Female	4	2.9	nc	(nc-nc)	Female	13	17.9	72.5	(38.6-124.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	13	17.9	72.8	(38.7-124.5)	Female	43	44.6	96.3	(69.7-129.8)
Female	16	16.3	97.9	(55.9-159.0)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	831	766.2	108.5	(101.2-116.1)
Male	7	10.7	65.5	(26.2-134.9)	Female	750	766.4	97.9	(91.0-105.1)
Female	5	4.7	107.1	(34.5-249.9)					
<u>Lung and Bronchus</u>									
Male	127	111.3	114.1	(95.1-135.7)					
Female	121	109.2	110.8	(91.9-132.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plainfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	2	2.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	1.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Male</u>				
Male	0	0.1	nc	(nc-nc)	6	11.0	54.8	(20.0-119.3)	
Female	0	0.0	nc	(nc-nc)	<u>Female</u>				
<u>Leukemia</u>					6				
Male	0	0.2	nc	(nc-nc)	7.4	80.8	(29.5-175.9)		
Female	0	0.1	nc	(nc-nc)	<u>Liver and Intrahepatic Bile Ducts</u>				
Male	0	0.2	nc	(nc-nc)	<u>Lung and Bronchus</u>				
Female	0	0.0	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
<u>Lung and Bronchus</u>					Female	1	1.0	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plainville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	7.7	65.3	(21.0-152.3)	Male	7	4.3	162.2	(65.0-334.2)
Female	5	2.7	183.0	(59.0-427.0)	Female	5	3.5	141.6	(45.6-330.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.6	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	3	1.3	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	4.1	122.3	(39.4-285.3)
Female	29	29.9	96.9	(64.9-139.2)	Female	1	3.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.4	nc	(nc-nc)	Male	0	3.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	13	11.7	111.1	(59.1-190.0)	Female	2	3.1	nc	(nc-nc)
Female	9	11.0	82.0	(37.4-155.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	2.2	nc	(nc-nc)
Male	1	2.0	nc	(nc-nc)	Female	4	2.3	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	41	32.0	128.2	(92.0-174.0)
Male	2	0.7	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.6	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.1	nc	(nc-nc)
Male	7	3.3	211.0	(84.5-434.8)	<u>Testis</u>				
Female	5	2.1	240.6	(77.6-561.6)	Male	2	1.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.4	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	5	2.9	170.2	(54.9-397.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	2.5	nc	(nc-nc)	Female	4	6.1	nc	(nc-nc)
Female	1	2.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	114	105.3	108.2	(89.3-130.0)
Male	0	1.5	nc	(nc-nc)	Female	107	98.0	109.2	(89.5-132.0)
Female	1	0.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	20	14.9	134.6	(82.2-207.9)					
Female	18	13.4	134.6	(79.7-212.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plymouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	61	48.1	126.9	(97.0-163.0)	Male	42	27.8	151.1	(108.9-204.3)
Female	17	17.7	95.8	(55.8-153.4)	Female	22	23.1	95.2	(59.6-144.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	11	10.2	108.2	(53.9-193.7)	Male	12	7.1	168.0	(86.7-293.5)
Female	15	8.8	170.9	(95.6-281.9)	Female	8	5.8	138.5	(59.6-272.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.5	nc	(nc-nc)	Male	33	26.2	125.8	(86.6-176.6)
Female	208	194.8	106.8	(92.8-122.3)	Female	24	23.6	101.5	(65.0-151.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	13	9.0	144.2	(76.7-246.6)	Male	31	19.6	158.0	(107.3-224.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	97	74.1	130.9	(106.2-159.7)	Female	19	20.5	92.7	(55.8-144.8)
Female	81	74.3	109.1	(86.6-135.5)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	11	12.2	89.8	(44.8-160.7)	Male	263	194.1	135.5	(119.6-152.9)
Female	5	3.5	141.5	(45.6-330.2)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	4	4.6	nc	(nc-nc)	Male	10	8.6	116.9	(56.0-215.1)
Female	4	3.7	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	28	20.8	134.6	(89.4-194.5)	Female	36	38.9	92.6	(64.9-128.2)
Female	16	13.3	120.6	(68.9-195.8)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Male</u>				
Male	12	8.6	139.6	(72.0-243.8)	Male	844	657.7	128.3	(119.8-137.3)
Female	2	2.3	nc	(nc-nc)	Female	678	639.9	105.9	(98.1-114.2)
<u>Leukemia</u>					<u>Female</u>				
Male	24	15.9	150.6	(96.5-224.1)					
Female	22	13.6	162.1	(101.6-245.5)					
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	5	9.8	51.1	(16.5-119.2)					
Female	7	3.6	192.3	(77.0-396.3)					
<u>Lung and Bronchus</u>									
Male	103	91.1	113.1	(92.3-137.1)					
Female	98	83.5	117.4	(95.3-143.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plympton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.1	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	12	9.3	129.7	(67.0-226.6)	Female	3	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	5	3.3	150.8	(48.6-351.9)	Female	3	0.9	nc	(nc-nc)
Female	3	2.7	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	0.6	nc	(nc-nc)
Male	2	0.6	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	7	9.6	73.2	(29.3-150.9)
Male	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.3	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.6	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.4	nc	(nc-nc)	Male	2	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	3	1.0	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	0.7	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	27	31.0	87.0	(57.3-126.6)
Male	0	0.5	nc	(nc-nc)	Female	42	27.5	152.6	(109.9-206.2)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	3	4.2	nc	(nc-nc)					
Female	7	3.3	211.9	(84.9-436.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Princeton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	3.0	200.7	(73.3-436.9)	Male	3	1.9	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	5	1.4	351.1	(113.2-819.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.7	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	10	12.3	81.2	(38.9-149.4)	Female	1	1.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.6	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	5	4.7	105.7	(34.1-246.7)	Female	0	1.2	nc	(nc-nc)
Female	0	3.6	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	0.9	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	13	13.3	98.0	(52.1-167.6)
Male	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	0.4	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	<u>Testis</u>				
Female	1	0.8	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	0.6	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	1.0	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	46	43.5	105.7	(77.4-141.0)
Male	1	0.7	nc	(nc-nc)	Female	25	36.6	68.3	(44.2-100.8)
Female	0	0.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	5	6.0	84.0	(27.1-195.9)					
Female	0	4.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Provincetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	5.2	212.4	(105.9-380.1)	Male	5	2.8	175.7	(56.6-410.0)
Female	2	1.7	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.9	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	2.7	nc	(nc-nc)
Female	18	17.1	105.0	(62.2-166.0)	Female	2	2.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.7	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	10	7.9	126.4	(60.5-232.5)	Female	1	1.8	nc	(nc-nc)
Female	11	7.0	157.8	(78.6-282.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	1.5	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	19	20.9	90.9	(54.7-141.9)
Male	3	0.4	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.2	nc	(nc-nc)	Male	3	1.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	0.8	nc	(nc-nc)
Male	5	2.2	231.0	(74.5-539.1)	<u>Testis</u>				
Female	2	1.2	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	0.9	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	1.5	nc	(nc-nc)	Female	3	3.5	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	95	69.2	137.3	(111.1-167.8)
Male	1	1.0	nc	(nc-nc)	Female	73	57.0	128.0	(100.3-161.0)
Female	1	0.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	13	9.8	132.5	(70.5-226.5)					
Female	16	7.7	207.3	(118.4-336.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Quincy

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	91	99.7	91.3	(73.5-112.1)	Male	66	52.6	125.5	(97.0-159.6)
Female	48	40.5	118.5	(87.4-157.2)	Female	45	46.4	97.1	(70.8-129.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	19	18.1	104.7	(63.0-163.6)	Male	18	14.3	125.6	(74.4-198.6)
Female	17	17.4	97.9	(57.0-156.8)	Female	15	13.2	113.8	(63.7-187.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	3.1	nc	(nc-nc)	Male	64	50.6	126.4	(97.3-161.4)
Female	383	390.8	98.0	(88.4-108.3)	Female	44	51.8	85.0	(61.7-114.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	15	17.1	87.8	(49.1-144.8)	Male	40	36.0	111.1	(79.4-151.3)
					Female	17	20.2	84.2	(49.0-134.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	177	149.9	118.1	(101.3-136.8)	Female	37	42.1	88.0	(61.9-121.3)
Female	183	167.9	109.0	(93.8-126.0)					
<u>Esophagus</u>					<u>Pancreas</u>				
Male	26	24.3	107.2	(70.0-157.1)	Male	33	28.2	117.0	(80.5-164.3)
Female	3	8.0	nc	(nc-nc)	Female	34	35.6	95.5	(66.2-133.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	9	8.3	108.9	(49.7-206.7)	Male	270	393.6	68.6	(60.7-77.3)
Female	3	7.4	nc	(nc-nc)					
<u>Kidney & Renal Pelvis</u>					<u>Stomach</u>				
Male	28	39.9	70.3	(46.7-101.5)	Male	22	25.4	86.8	(54.4-131.4)
Female	20	28.6	70.0	(42.7-108.1)	Female	24	17.9	134.0	(85.8-199.4)
<u>Larynx</u>					<u>Testis</u>				
Male	24	16.8	142.5	(91.3-212.0)	Male	15	15.6	96.1	(53.8-158.6)
Female	7	5.0	138.9	(55.6-286.1)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	20	30.6	65.3	(39.8-100.8)	Male	7	10.6	66.1	(26.5-136.2)
Female	15	28.6	52.4	(29.3-86.5)	Female	41	36.1	113.5	(81.4-153.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	37	18.5	200.5	(141.1-276.3)	Female	76	79.4	95.8	(75.5-119.9)
Female	12	8.1	147.5	(76.1-257.7)					
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	216	187.8	115.0	(100.2-131.4)	Male	1283	1312.7	97.7	(92.5-103.2)
Female	245	189.3	129.4	(113.7-146.7)	Female	1379	1355.3	101.8	(96.5-107.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Randolph

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	32	34.6	92.5	(63.2-130.6)	Male	12	18.5	64.8	(33.4-113.2)
Female	16	12.7	126.2	(72.1-205.0)	Female	9	15.5	58.2	(26.6-110.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	6.5	nc	(nc-nc)	Male	6	5.0	119.2	(43.5-259.5)
Female	8	5.8	136.9	(59.0-269.8)	Female	2	4.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.1	nc	(nc-nc)	Male	16	17.7	90.2	(51.5-146.5)
Female	121	132.9	91.1	(75.6-108.8)	Female	17	16.5	102.8	(59.9-164.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	5.9	nc	(nc-nc)	Male	10	13.1	76.2	(36.5-140.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	57	52.5	108.6	(82.3-140.7)	Female	17	14.0	121.2	(70.5-194.0)
Female	59	51.9	113.6	(86.5-146.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	7	9.9	70.6	(28.3-145.4)
Male	6	8.6	69.6	(25.4-151.5)	Female	11	11.0	100.2	(49.9-179.3)
Female	3	2.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	147	140.1	104.9	(88.6-123.3)
Male	1	2.8	nc	(nc-nc)	<u>Stomach</u>				
Female	4	2.4	nc	(nc-nc)	Male	10	8.8	113.3	(54.3-208.4)
<u>Kidney & Renal Pelvis</u>					Female	4	5.5	nc	(nc-nc)
Male	14	14.3	97.8	(53.4-164.1)	<u>Testis</u>				
Female	8	9.3	85.6	(36.9-168.7)	Male	5	4.8	103.9	(33.5-242.5)
<u>Larynx</u>					<u>Thyroid</u>				
Male	5	6.0	82.9	(26.7-193.4)	Male	4	3.7	nc	(nc-nc)
Female	3	1.7	nc	(nc-nc)	Female	15	12.4	120.9	(67.6-199.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	10.8	74.1	(31.9-146.0)	Female	17	27.0	62.9	(36.6-100.8)
Female	10	9.1	109.3	(52.3-201.0)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	441	462.5	95.4	(86.7-104.7)
Male	7	6.7	105.0	(42.1-216.4)	Female	461	442.9	104.1	(94.8-114.0)
Female	2	2.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	61	65.9	92.5	(70.8-118.8)					
Female	87	60.7	143.2	(114.7-176.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Raynham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	12.1	91.3	(45.5-163.3)	Male	3	6.7	nc	(nc-nc)
Female	2	4.4	nc	(nc-nc)	Female	5	5.6	89.2	(28.7-208.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	2.4	209.7	(67.6-489.3)	Male	2	1.8	nc	(nc-nc)
Female	3	2.1	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	11	6.3	173.7	(86.6-310.8)
Female	42	48.3	86.9	(62.6-117.5)	Female	3	5.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	2.2	nc	(nc-nc)	Male	5	4.8	104.2	(33.6-243.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	24	18.4	130.1	(83.3-193.6)	Female	3	5.1	nc	(nc-nc)
Female	20	18.0	110.8	(67.7-171.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	3.5	171.5	(62.6-373.4)
Male	5	3.1	162.9	(52.5-380.1)	Female	8	3.8	210.1	(90.5-414.0)
Female	0	0.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	76	49.9	152.3	(120.0-190.6)
Male	2	1.0	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.9	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.9	nc	(nc-nc)
Male	4	5.2	nc	(nc-nc)	<u>Testis</u>				
Female	1	3.3	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	2.2	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	8	4.6	174.7	(75.2-344.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	3.9	155.5	(56.8-338.4)	Female	7	9.8	71.1	(28.5-146.6)
Female	6	3.3	184.2	(67.3-400.9)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	215	164.2	130.9	(114.0-149.6)
Male	3	2.4	nc	(nc-nc)	Female	154	158.3	97.3	(82.5-113.9)
Female	0	0.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	30	23.2	129.2	(87.1-184.4)					
Female	30	21.5	139.8	(94.3-199.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Reading

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	26	25.7	101.1	(66.0-148.2)	Male	24	14.0	171.5	(109.8-255.2)
Female	10	9.6	103.8	(49.7-190.9)	Female	21	11.7	179.3	(111.0-274.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	5.0	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)
Female	6	4.5	134.1	(49.0-291.9)	Female	2	3.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	12	13.3	90.1	(46.5-157.4)
Female	144	102.2	140.9	(118.8-165.9)	Female	13	12.5	103.6	(55.1-177.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	4.5	111.2	(35.8-259.5)	Male	2	9.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	36	39.1	92.1	(64.5-127.5)	Female	20	10.7	186.4	(113.8-287.9)
Female	41	39.4	104.0	(74.6-141.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	7.4	81.2	(29.7-176.8)
Male	5	6.5	77.5	(25.0-180.9)	Female	4	8.3	nc	(nc-nc)
Female	3	1.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	111	104.5	106.2	(87.4-127.9)
Male	2	2.0	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.7	nc	(nc-nc)	Male	7	6.6	106.6	(42.7-219.7)
<u>Kidney & Renal Pelvis</u>					Female	1	4.1	nc	(nc-nc)
Male	12	10.8	110.8	(57.2-193.5)	<u>Testis</u>				
Female	7	7.1	98.0	(39.3-201.9)	Male	5	3.5	141.1	(45.5-329.2)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	4.5	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	13	9.3	139.2	(74.1-238.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	8.1	nc	(nc-nc)	Female	20	20.6	97.0	(59.2-149.8)
Female	5	7.0	71.2	(22.9-166.2)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	330	345.8	95.4	(85.4-106.3)
Male	5	5.1	98.6	(31.8-230.2)	Female	392	337.9	116.0	(104.8-128.1)
Female	1	1.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	49	49.3	99.4	(73.6-131.5)					
Female	38	46.2	82.3	(58.3-113.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rehoboth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	9.5	126.9	(65.5-221.7)	Male	11	5.8	190.8	(95.1-341.5)
Female	2	3.1	nc	(nc-nc)	Female	12	4.6	263.5	(136.0-460.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.1	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	5.3	93.7	(30.2-218.7)
Female	38	39.1	97.2	(68.8-133.4)	Female	3	4.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.9	nc	(nc-nc)	Male	1	4.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	13	14.9	87.5	(46.5-149.6)	Female	0	4.0	nc	(nc-nc)
Female	10	12.5	79.7	(38.2-146.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	2.8	nc	(nc-nc)
Male	1	2.6	nc	(nc-nc)	Female	3	2.6	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	49	42.0	116.7	(86.3-154.3)
Male	1	0.9	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.7	nc	(nc-nc)	Male	0	2.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.3	nc	(nc-nc)
Male	10	4.5	224.1	(107.3-412.1)	<u>Testis</u>				
Female	3	2.5	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.9	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	6	4.0	150.5	(55.0-327.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	3.2	nc	(nc-nc)	Female	4	7.9	nc	(nc-nc)
Female	5	2.4	210.0	(67.7-490.2)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	136	136.3	99.8	(83.7-118.0)
Male	1	2.1	nc	(nc-nc)	Female	107	120.9	88.5	(72.5-106.9)
Female	1	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	17	18.8	90.6	(52.8-145.1)					
Female	11	15.6	70.6	(35.2-126.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Revere

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	87	56.8	153.2	(122.7-189.0)	Male	21	29.0	72.5	(44.9-110.9)
Female	25	21.2	118.0	(76.3-174.2)	Female	26	23.8	109.2	(71.3-160.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	10.0	99.9	(47.8-183.8)	Male	5	8.1	61.7	(19.9-144.0)
Female	9	9.1	99.0	(45.2-187.9)	Female	8	6.9	115.6	(49.8-227.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.7	nc	(nc-nc)	Male	28	28.1	99.6	(66.2-143.9)
Female	198	204.6	96.8	(83.8-111.2)	Female	29	27.0	107.4	(71.9-154.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	14	8.8	159.7	(87.2-267.9)	Male	18	19.9	90.5	(53.6-143.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	88	84.9	103.6	(83.1-127.7)	Female	22	22.0	100.1	(62.7-151.5)
Female	108	87.4	123.5	(101.3-149.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	22	16.0	137.6	(86.2-208.3)
Male	14	13.7	102.5	(56.0-172.0)	Female	29	18.6	156.3	(104.6-224.5)
Female	4	4.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	171	222.1	77.0	(65.9-89.4)
Male	7	4.3	163.2	(65.4-336.2)	<u>Stomach</u>				
Female	9	3.7	241.8	(110.3-459.0)	Male	21	14.3	146.4	(90.6-223.8)
<u>Kidney & Renal Pelvis</u>					Female	18	9.3	193.9	(114.9-306.5)
Male	24	22.3	107.6	(68.9-160.1)	<u>Testis</u>				
Female	21	15.0	139.7	(86.4-213.5)	Male	13	7.7	169.6	(90.2-290.0)
<u>Larynx</u>					<u>Thyroid</u>				
Male	8	9.5	84.6	(36.4-166.7)	Male	8	5.6	142.8	(61.5-281.3)
Female	6	2.7	223.6	(81.7-486.8)	Female	23	18.2	126.1	(79.9-189.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	22	17.3	127.4	(79.8-192.9)	Female	35	41.8	83.7	(58.3-116.4)
Female	16	15.0	106.7	(60.9-173.3)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	779	738.3	105.5	(98.2-113.2)
Male	15	10.3	145.9	(81.6-240.7)	Female	785	707.9	110.9	(103.3-118.9)
Female	2	4.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	143	106.8	133.9	(112.8-157.7)					
Female	125	99.7	125.3	(104.3-149.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Richmond

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	2.3	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	3	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	9	8.4	107.6	(49.1-204.4)	Female	0	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.3	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	3.5	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Female	1	3.0	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.6	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.1	nc	(nc-nc)	Male	11	10.1	109.4	(54.5-195.7)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	0	1.0	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.7	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	0.5	nc	(nc-nc)	Female	3	1.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	5	4.5	111.2	(35.8-259.6)	Male	26	31.4	82.7	(54.0-121.2)
Female	2	3.7	nc	(nc-nc)	Female	21	26.6	78.9	(48.8-120.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rochester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	4.0	125.6	(40.5-293.2)	Male	2	2.5	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	Female	3	2.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.9	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	3	0.7	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
Female	12	16.6	72.2	(37.3-126.2)	Female	0	1.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.8	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	6	6.3	95.1	(34.7-207.0)	Female	4	1.7	nc	(nc-nc)
Female	4	5.2	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	1.2	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	18	17.4	103.3	(61.2-163.2)
Male	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.5	nc	(nc-nc)
Male	2	1.9	nc	(nc-nc)	<u>Testis</u>				
Female	1	1.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	0.8	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	1.4	nc	(nc-nc)	Female	7	3.3	213.2	(85.4-439.3)
Female	1	1.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	52	57.7	90.1	(67.3-118.2)
Male	0	0.9	nc	(nc-nc)	Female	52	50.6	102.7	(76.7-134.7)
Female	0	0.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	7	7.9	89.2	(35.7-183.7)					
Female	7	6.3	111.0	(44.5-228.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rockland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	16.7	125.5	(77.7-191.8)	Male	11	9.3	118.2	(58.9-211.5)
Female	4	6.6	nc	(nc-nc)	Female	6	8.3	72.2	(26.4-157.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	3.4	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	4	3.2	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	12	8.9	135.3	(69.8-236.4)
Female	75	70.2	106.9	(84.1-134.0)	Female	8	8.7	91.9	(39.6-181.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.2	nc	(nc-nc)	Male	11	6.5	169.4	(84.5-303.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	29	25.5	113.8	(76.2-163.5)	Female	5	7.4	67.6	(21.8-157.9)
Female	26	26.9	96.6	(63.1-141.6)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	4	4.2	nc	(nc-nc)	Male	60	68.3	87.9	(67.1-113.1)
Female	0	1.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	3	1.5	nc	(nc-nc)	Male	0	2.7	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	7.1	70.3	(22.7-164.1)	Female	17	14.2	119.5	(69.6-191.3)
Female	6	4.9	121.5	(44.4-264.5)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Liver and Intrahepatic Bile Ducts</u>				
Male	2	2.9	nc	(nc-nc)	Male	4	3.3	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Leukemia</u>					<u>Lung and Bronchus</u>				
Male	7	5.5	128.0	(51.3-263.8)	Male	49	32.2	152.0	(112.5-201.0)
Female	4	4.9	nc	(nc-nc)	Female	40	32.0	125.1	(89.4-170.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rockport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	11.3	79.7	(36.3-151.2)	Male	1	5.6	nc	(nc-nc)
Female	3	4.5	nc	(nc-nc)	Female	5	4.8	104.9	(33.8-244.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.9	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
Female	3	1.8	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	2	5.4	nc	(nc-nc)
Female	40	43.7	91.4	(65.3-124.5)	Female	5	5.7	88.2	(28.4-205.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.7	nc	(nc-nc)	Male	5	4.0	124.7	(40.2-291.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	6	17.0	35.4	(12.9-77.0)	Female	4	4.7	nc	(nc-nc)
Female	11	18.9	58.1	(28.9-103.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	3.2	nc	(nc-nc)
Male	3	2.7	nc	(nc-nc)	Female	2	4.0	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	39	43.3	90.1	(64.0-123.2)
Male	2	0.7	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.6	nc	(nc-nc)	Male	4	2.9	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	4	2.0	nc	(nc-nc)
Male	2	4.4	nc	(nc-nc)	<u>Testis</u>				
Female	2	3.2	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.9	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	3	3.4	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	3.3	nc	(nc-nc)	Female	9	8.9	101.0	(46.1-191.7)
Female	4	3.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	109	144.1	75.6	(62.1-91.3)
Male	3	2.0	nc	(nc-nc)	Female	138	149.8	92.1	(77.4-108.8)
Female	0	0.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	13	20.8	62.5	(33.3-106.9)					
Female	24	21.1	113.7	(72.8-169.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rowe

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	0.6	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	2.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	0.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	1	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.1	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	2	1.1	nc	(nc-nc)	Male	7	7.8	90.0	(36.1-185.5)
Female	2	0.9	nc	(nc-nc)	Female	5	6.3	79.2	(25.5-184.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rowley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	4.3	184.6	(79.5-363.7)	Male	3	2.7	nc	(nc-nc)
Female	3	1.6	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	2.5	nc	(nc-nc)
Female	15	19.6	76.5	(42.8-126.2)	Female	4	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.0	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	6	6.8	88.3	(32.2-192.2)	Female	3	2.0	nc	(nc-nc)
Female	7	6.8	103.1	(41.3-212.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	1.3	nc	(nc-nc)
Male	3	1.2	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	22	18.2	121.0	(75.8-183.2)
Male	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.7	nc	(nc-nc)
Male	1	2.0	nc	(nc-nc)	<u>Testis</u>				
Female	1	1.3	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	2.1	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.5	nc	(nc-nc)	Female	0	3.8	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	66	61.8	106.8	(82.6-135.9)
Male	1	1.0	nc	(nc-nc)	Female	53	62.0	85.4	(64.0-111.7)
Female	0	0.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	7	8.4	83.6	(33.5-172.3)					
Female	5	7.7	64.6	(20.8-150.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Royalston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.2	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
Female	3	4.2	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	1.8	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	4	1.5	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	6	4.9	122.2	(44.6-266.0)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.2	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.4	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	17	16.4	103.8	(60.4-166.2)
Male	0	0.3	nc	(nc-nc)	Female	14	13.4	104.4	(57.1-175.3)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	0	2.3	nc	(nc-nc)					
Female	4	1.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;